Abstract:Acute kidney injury (AKI) is associated with significant morbidity and its chronic inflammation contributes to subsequent chronic kidney disease (CKD) development. Yes-associated protein (YAP), the major transcriptional coactivator of the Hippo pathway, has been shown associated with chronic inflammation, but its role and mechanism in AKI-CKD transition remain unclear. Here we aimed to investigate the role of YAP in AKI-induced chronic inflammation. Renal ischemia/reperfusion (I/R) was used to induce a mouse model of AKI-CKD transition. We used verteporfin (VP), a pharmacological inhibitor of YAP, to treat post-IRI mice for a period, and evaluated the influence of YAP inhibition on long-term outcomes of AKI. In our results, severe IRI led to maladaptive tubular repair, macrophages infiltration, and progressive fibrosis. Following AKI, the Hippo pathway was found significantly altered with YAP persistent activation. Besides, tubular YAP activation was associated with the maladaptive repair, also correlated with interstitial macrophage infiltration. Monocyte chemoattractant protein 1 (MCP-1) was found notably upregulated with YAP activation. Of note, pharmacological inhibition of YAP in vivo attenuated renal inflammation, including macrophage infiltration and MCP-1 overexpression. Consistently, in vitro oxygen-glucose deprivation and reoxygenation (OGD/R) induced YAP activation and MCP-1 overproduction whereas these could be inhibited by VP. In addition, we modulated YAP activity by RNA interference, which further confirmed YAP activation enhances MCP-1 expression. Together, we concluded tubular YAP activation with maladaptive repair exacerbates renal inflammation probably via promoting MCP-1 production, which contributes to AKI-CKD transition.

Kidney tubular transcription co-activator, Yes-associated protein 1 (YAP), controls the expression of collecting duct aquaporins and water homeostasis

YAP promotes AP-1 expression in tubular epithelial cells in the kidney.

Activation of the YAP/KLF5 Transcriptional Cascade in Renal Tubular Cells Aggravates Kidney Injury.

Tubule-Specific Mst1/2 Deficiency Induces CKD Via YAP and Non-YAP Mechanisms.

YAP/TAZ and Renal Diseases

Inactivation of Yap Oncoprotein by the Hippo Pathway is Involved in Cell Contact Inhibition and Tissue Growth Control

The Role of YAP Transcription Coactivator in Regulating Stem Cell Self-Renewal and Differentiation.

Integration of Mechanical and Chemical Signals by YAP and TAZ Transcription Coactivators.

The Regulation and Function of YAP Transcription Co-Activator

A Coordinated Phosphorylation By Lats And Ck1 Regulates Yap Stability Through Scf Beta-Trcp

Angiomotin is a Novel Hippo Pathway Component That Inhibits YAP Oncoprotein.

Molecular mechanisms of the mammalian Hippo signaling pathway.

Yap- and Cdc42-Dependent Nephrogenesis and Morphogenesis during Mouse Kidney Development

The Hippo-YAP Pathway in Organ Size Control and Tumorigenesis: an Updated Version.

The Hippo-YAP pathway: new connections between regulation of organ size and cancer.

Integration of Hippo Signalling and the Unfolded Protein Response to Restrain Liver Overgrowth and Tumorigenesis

TEAD Mediates YAP-dependent Gene Induction and Growth Control

Harness the power: new insights into the inhibition of YAP/Yorkie.

A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.

YAP-VGLL4 antagonism defines the major physiological function of the Hippo signaling effector YAP

Hippo-YAP/MCP-1 Mediated Tubular Maladaptive Repair Promote Inflammation in Renal Failed Recovery after Ischemic AKI.